This site is intended for US healthcare professionals
Alkermes logo
Alkermes logo
Educational Resources
Resources Home
Congresses
Product Information
Our Pipeline
Knowledge Vault
Contact an MSL
Medical Information
Research & Medical Grants

Product Information

LYBALVI®

(olanzapine and samidorphan)

Prescribing Information Medication Guide

Publications

Alkermes Sponsored Phase 3 Clinical Trials

Mar 2020
Efficacy and Safety of a Combination of Olanzapine and Samidorphan in Adult Patients With an Acute Exacerbation of Schizophrenia: Outcomes From the Randomized, Phase 3 ENLIGHTEN-1 Study
The Journal of Clinical Psychiatry
AUTHOR(S)

Potkin SG, Kunovac J, Silverman BL, Simmons A, Jiang Y, DiPetrillo L, McDonnell D

View on PubMed
Dec 2020
Effects of Olanzapine Combined With Samidorphan on Weight Gain in Schizophrenia: A 24-Week Phase 3 Study
The American Journal of Psychiatry
AUTHOR(S)

Correll CU, Newcomer JW, Silverman B, DiPetrillo L, Graham C, Jiang Y, Du Y, Simmons A, Hopkinson C, McDonnell D, Kahn RS

View on PubMed
Jun 2021
A phase 3, multicenter study to assess the 1-year safety and tolerability of a combination of olanzapine and samidorphan in patients with schizophrenia: Results from the ENLIGHTEN-2 long-term extension.
Schizophrenia Research
AUTHOR(S)

Kahn RS, Silverman BL, DiPetrillo L, Graham C, Jiang Y, Yin J, Simmons A, Bhupathi V, Yu B, Yagoda S, Hopkinson C, McDonnell D

View on PubMed
Aug 2021
Long-term safety and durability of effect with a combination of olanzapine and samidorphan in patients with schizophrenia: results from a 1-year open-label extension study
CNS Spectrums
AUTHOR(S)

Yagoda S, Graham C, Simmons A, Arevalo C, Jiang Y, McDonnell D

View on PubMed
Contact Us Terms of Use Privacy Policy www.alkermes.com

The product information provided on this site is intended only for healthcare professionals in the United States and is for informational purposes only. This site is designed to provide background and scientific findings concerning Alkermes products and areas of therapeutic interest. Information about pipeline products or investigational uses of products does not imply FDA approval for these products or uses, nor does it establish the safety or efficacy of these products or uses. There is no guarantee that the pipeline products or investigational uses will receive FDA approval. Alkermes does not recommend or suggest use of its medicines in a manner inconsistent with FDA-approved labeling.

If you have a suspected Adverse Event or Product Complaint to report, please contact us by phone at 888-235-8008 or contact the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch

Your use of this information is subject to the terms and conditions of our Privacy Policy.

© 2024 Alkermes, Inc. All rights reserved. MA-004230

Please review our Privacy Policy.

By using our website without changing your cookie settings you agree to our use of cookies as described in our Privacy Policy. Learn more.

Close
This site is intended for US healthcare professionals
Alkermes Logo
Educational Resources
Congresses
Product Information
Our Pipeline
Contact an MSL
Medical Information
Research & Medical Grants